| CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer’s disease F Djelti, J Braudeau, E Hudry, M Dhenain, J Varin, I Bieche, C Marquer, ... Brain 138 (8), 2383-2398, 2015 | 205 | 2015 |
| Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice J Braudeau, B Delatour, A Duchon, PL Pereira, L Dauphinot, ... Journal of psychopharmacology 25 (8), 1030-1042, 2011 | 204 | 2011 |
| Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model R Fol, J Braudeau, S Ludewig, T Abel, SW Weyer, JP Roederer, F Brod, ... Acta neuropathologica 131, 247-266, 2016 | 188 | 2016 |
| Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice S Alves, G Churlaud, M Audrain, K Michaelsen-Preusse, R Fol, B Souchet, ... Brain 140 (3), 826-842, 2017 | 162 | 2017 |
| Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology MA Burlot, J Braudeau, K Michaelsen-Preusse, B Potier, S Ayciriex, ... Human molecular genetics 24 (21), 5965-5976, 2015 | 126 | 2015 |
| Activation of proinflammatory caspases by cathepsin B in focal cerebral ischemia A Benchoua, J Braudeau, A Reis, C Couriaud, B Onténiente Journal of Cerebral Blood Flow & Metabolism 24 (11), 1272-1279, 2004 | 107 | 2004 |
| Chronic treatment with a promnesiant GABA‐A α5‐selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their … J Braudeau, L Dauphinot, A Duchon, A Loistron, RH Dodd, Y Hérault, ... Advances in Pharmacological and Pharmaceutical Sciences 2011 (1), 153218, 2011 | 66 | 2011 |
| PTD–XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms C Guégan, J Braudeau, C Couriaud, GPH Dietz, P Lacombe, M Bähr, ... Neurobiology of disease 22 (1), 177-186, 2006 | 65 | 2006 |
| The mechanisms of cell death in focal cerebral ischemia highlight neuroprotective perspectives by anti-caspase therapy B Onténiente, C Couriaud, J Braudeau, A Benchoua, C Guégan Biochemical pharmacology 66 (8), 1643-1649, 2003 | 52 | 2003 |
| Alzheimer’s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression M Audrain, R Fol, P Dutar, B Potier, JM Billard, J Flament, S Alves, ... Molecular neurodegeneration 11, 1-17, 2016 | 46 | 2016 |
| Real-time monitoring of exosome enveloped-AAV spreading by endomicroscopy approach: a new tool for gene delivery in the brain NS Orefice, B Souchet, J Braudeau, S Alves, F Piguet, F Collaud, ... Molecular Therapy Methods & Clinical Development 14, 237-251, 2019 | 41 | 2019 |
| Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice B Souchet, M Audrain, JM Billard, J Dairou, R Fol, NS Orefice, S Tada, ... Acta neuropathologica communications 7, 1-15, 2019 | 40 | 2019 |
| Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome MC Potier, J Braudeau, L Dauphinot, B Delatour CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2014 | 38 | 2014 |
| βAPP processing drives gradual tau pathology in an age-dependent amyloid rat model of Alzheimer’s disease M Audrain, B Souchet, S Alves, R Fol, A Viode, A Haddjeri, S Tada, ... Cerebral Cortex 28 (11), 3976-3993, 2018 | 22 | 2018 |
| Cerebral phospho-tau acts synergistically with soluble Aβ42 leading to mild cognitive impairment in AAV-AD rats B Souchet, M Audrain, Y Gu, MF Lindberg, NS Orefice, E Rey, N Cartier, ... The Journal of Prevention of Alzheimer's Disease 9 (3), 480-490, 2022 | 7 | 2022 |
| Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? B Souchet, M Audrain, B Billoir, L Lecanu, S Tada, J Braudeau Neural regeneration research 13 (2), 224-225, 2018 | 7 | 2018 |
| Transient increase in sAPPα secretion in response to Aβ1–42 oligomers: an attempt of neuronal self-defense? C Rose, E Dorard, M Audrain, L Gorisse-Hussonnois, N Cartier, ... Neurobiology of Aging 61, 23-35, 2018 | 7 | 2018 |
| Evaluation of Memantine in AAV-AD Rat: a model of late-onset Alzheimer’s Disease Predementia B Souchet, M Audrain, S Alves, R Fol, S Tada, NS Orefice, B Potier, ... The Journal of prevention of Alzheimer's disease 9 (2), 338-347, 2022 | 5 | 2022 |
| Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research? B Souchet, A Michaïl, B Billoir, J Braudeau International Journal of Molecular Sciences 24 (24), 17544, 2023 | 2 | 2023 |
| O5‐06‐04: AAV‐CYP46A1 BRAIN DELIVERY MITIGATES ALZHEIMER'S DISEASE: FROM MOUSE MODELS TO NON‐HUMAN PRIMATES S Alves, K Michaelsen-Preusse, M Audrain, RA Badin, A Lamazière, ... Alzheimer's & Dementia 14 (7S_Part_31), P1658-P1659, 2018 | 2 | 2018 |
